Mineralys Therapeutics, Inc.

Mineralys Therapeutics (MLYS) shows no detected cyber incidents or red-flag 8-K filings in our 90-day monitoring window, suggesting operational stability in the recent period. However, the absence of near-term signals does not preclude longer-term risks; a biotech company's true risk profile requires deeper context on dilution trajectories, financing history, and AI-detected anomalies. The full $49 Report extends analysis to 12 months of filings, calculates shareholder dilution risk scores, contextualizes all 8-K activity, and surfaces emerging financial stress signals invisible to standard screening. This deeper view transforms a clean recent snapshot into actionable risk intelligence.